Changes in Control of Registrant The information set forth in the Introductory Note and in Items 2.01, 2.03, and 5.02 of this Current Report on Form 8-K is incorporated by reference in this

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information set forth in the Introductory Note and in

At the Effective Time, each holder of shares of Common Stock outstanding immediately prior to the Effective Time ceased to have any rights as a stockholder of the Company (other than the right to receive the Merger Consideration for such shares pursuant to the terms of the Merger Agreement).

Termination of a Material Definitive Agreement Concurrently with the closing of the Merger on the Closing Date, and in connection with the entry into the Credit Agreement, the Company repaid all loans and terminated all credit commitments outstanding under that certain Credit Agreement, dated as of June 24, 2022, by and among the Company, JPMorgan Chase Bank, N.A., as administrative agent, and the other parties thereto, as amended by the First Amendment to Credit Agreement, dated June 26, 2024.

On the Closing Date, Merger Subsidiary, as initial borrower, entered into a Credit Agreement (the “Credit Agreement”), with A-AV Acquireco, Inc., a Delaware corporation, as a borrower (“A-AV Acquireco Borrower” and together with the Company, the “Borrowers” and each, a “Borrower”), A-AV Intermediateco, LP, a Delaware limited partnership (“Holdings”), the guarantors from time to time party thereto (collectively, the “Guarantors”), Golub Capital Markets LLC, as term loan administrative agent an…

On the Closing Date, the Company notified the New York Stock Exchange (the “NYSE”) that the Merger had been completed and requested that the NYSE suspend trading of Common Stock on the NYSE prior to the opening of trading on the Closing Date. The Company also requested that the NYSE file with the SEC a notification of removal from listing and registration on Form 25 to effect the delisting of all shares of Common Stock from the NYSE and the deregistration of such shares under Section 12(b) of…

At the effective time of the Merger (the “Effective Time”), each share of the Company’s common stock, par value $0.01 per share (“Common Stock”), issued and outstanding immediately prior to the Effective Time (other than (i) shares of Common Stock held by Avanos as treasury stock or owned by any subsidiary of Avanos or by Parent or any subsidiary of Parent immediately prior to the Effective Time and (ii) shares of Common Stock held by a holder who is entitled to demand and properly demands ap…

Regulation FD Disclosure On the Closing Date, the Company and Parent issued a joint press release announcing the closing of the Merger. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Such press release shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Ac…

Gary D. Blackford, Dr. Lisa Egbuonu-Davis, Indrani L. Franchini, Patrick J. O’Leary, David C. Pacitti, Julie Shimer, Joel Rotroff: Directors resigned and new officers were appointed as part of a merger.

Other Events Supplement to Definitive Proxy Statement As previously disclosed, on April 13, 2026, Avanos Medical, Inc. (“Avanos” or the “Company”) entered into an Agreement and Plan of Merger (as it has been or may be amended, supplemented, waived or otherwise modified in accordance with its terms, the “Merger Agreement”), by and among Avanos, A-AV Holdco I, Inc., a Delaware corporation (“Parent”), and A-AV MergerSub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merg…

Regulation FD Disclosure On July 2, 2026, Avanos Medical, Inc., a Delaware corporation (the “Company”), issued a press release announcing the receipt of all required regulatory approvals to complete the pending acquisition of the Company by affiliates of investment funds advised by American Industrial Partners. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information furnished pursuant to

of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in

Entry into a Material Definitive Agreement. On April 13, 2026, Avanos Medical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, A-AV Holdco I, Inc., a Delaware corporation (“Parent”), and A-AV MergerSub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Subsidiary”). Upon the terms and conditions set forth in the Merger Agreement, Merger Subsidiary will be merged with and into the Company (the “Mer…

David C. Pacitti: The change involves a compensation adjustment, not a management movement.

Entry into a Material Definitive Agreement. On February 25, 2026, Avanos Medical, Inc. (the “Company”), entered into a letter agreement (the “Agreement”) with Bradley L. Radoff and The Radoff Family Foundation (collectively, the “Radoff Parties”). In connection with the Agreement, the Company’s Board of Directors (the “Board”) has agreed, among other things, to take all actions necessary to: (i) nominate James L. Cunniff to stand for election to the Board at the Company’s 2026 annual meeting…

Results of Operation and Financial Condition On February 24, 2026, Avanos Medical, Inc. (the "Company") issued a press release announcing its results of operations for the three months and year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. The information contained in this

Chief Commercial Officer — Kerr Holbrook: The company eliminated the positions of Chief Commercial Officer and General Counsel, resulting in the termination of two senior executives with significant severance packages.

Results of Operations and Financial Condition On November 5, 2025, Avanos Medical, Inc. (the “Company”) issued a press release announcing its results of operations for the three and nine months ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. The information contained in

Chief Commercial Officer, General Counsel — Kerr Holbrook, Mojirade James: The positions of Chief Commercial Officer and General Counsel were eliminated as part of a broader organizational restructuring.

Regulation FD Disclosure On September 15, 2025, Avanos Medical, Inc. (the “Company”) issued a press release announcing that the Company has acquired Nexus Medical, LLC. A copy of such press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein in its entirety. The information in

Results of Operations and Financial Condition On August 5, 2025, Avanos Medical, Inc. (the “Company”) issued a press release announcing its results of operations for the three and six months ended June 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. The information contained in

Regulation FD Disclosure On July 31, 2025, the Company issued a press release announcing the divestiture of its Hyaluronic Acid (HA) product line to Channel-Markers Medical, LLC. A copy of such press release is attached as Exhibit 99.2 hereto and is incorporated by reference herein in its entirety. On August 5, 2025, the Company issued a press release regarding the appointment of Mr. Pacitti to the Board, effective August 1, 2025, and the appointment of Mr. Galovan to the position of Senior V…

CFO — Scott Galovan: The filing discloses the internal promotion of Scott Galovan to CFO and the CEO's appointment to the Board, with no indication of a sudden executive departure or termination.

Results of Operations and Financial Condition On May 6, 2025, Avanos Medical, Inc. (the “Company”) issued a press release announcing its results of operations for the three months ended March 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. The information contained in

Director — Michael C. Greiner: The filing details the formal separation agreement and severance terms for Michael C. Greiner, confirming his departure from the company.